Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment After Autologous Hematopoietic Stem Cell Transplantation in Children With Neuroblastoma
Beijing Children's Hospital
30 participants
Jun 30, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is: · Does drug hetrombopag promote platelet engraftment? Participants will take hetrombopag every day for 6 weeks or until platelet \> 100\*10\^9/L.
Eligibility
Inclusion Criteria5
- Age\<18 years old;
- Diagnosed as neuroblastoma;
- ECOG ≤ 2;
- First time receiving autologous hematopoietic stem cell transplantation;
- The subjects or their legal guardians agree to participate and sign the informed consent form.
Exclusion Criteria4
- ALT/AST \> 3 ULN, or TBIL \> 1.5 ULN;
- Have experienced congestive heart failure, arrhythmia, peripheral arteriovenous thrombosis requiring medication treatment within one year prior to enrollment, or have experienced myocardial infarction or cerebral infarction within three months prior to enrollment;
- Suffering from thromboembolic diseases;
- Other situations that are not suitable for inclusion in the study determined by researchers.
Interventions
Patients enrolled were administered Hetrombopag starting from +4d after transplantation on routine medication of recombinant human thrombopoietin injection (rhTPO). The starting dose of Hetrombopag is 2.5mg or 5mg, oral, once daily (starting at 5mg/d for body weight\>20kg; starting from 2.5mg/d for body weight ≤ 20kg). Adjust the dosage based on platelet count every two weeks, with a maximum dose of 7.5mg per day. Stop the medication after 6 weeks of continuous use or when PLT reaches 100 × 10\^9/L.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06818916